Glutamine - Emmaus Medical

Drug Profile

Glutamine - Emmaus Medical

Alternative Names: Endari; L-glutamine - Emmaus Medical; Levoglutamide; NutreStore; PGLG - Emmaus Medical; SCD therapy; Xyndari

Latest Information Update: 26 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nutritional Restart Pharmaceutical
  • Developer Emmaus Medical; myTomorrows; Nutritional Restart Pharmaceutical
  • Class Antianaemics; Basic amino acids; Diamino amino acids; Neutral amino acids; Small molecules
  • Mechanism of Action Antioxidants; Protein synthesis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Short bowel syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Sickle cell anaemia

Highest Development Phases

  • Marketed Short bowel syndrome; Sickle cell anaemia
  • Phase III Thalassaemia

Most Recent Events

  • 19 Sep 2018 Emmaus Life Sciences enters into a distribution agreement with ASH Healthcare before September 2018
  • 19 Sep 2018 Emmaus Life Sciences enters into a distribution agreement with Cardinal Health
  • 19 Sep 2018 Launched for Sickle cell anaemia (In adolescents, In children, In adults) in Puerto Rico (PO) before September 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top